Brian Lau

Brian focuses his practice on initial public offerings on the Hong Kong Stock Exchange, as well as on Hong Kong listing rules and securities regulations compliance advisory work.

Brian is fluent in English, Mandarin and Cantonese.

Brian's representative matters include advising:

• China International Capital Corporation (CICC), Citigroup Global Markets Asia and Merrill Lynch (Asia Pacific) as joint sponsors for the IPO of Fenbi, an internet-born test preparation company
• Shukun Technology (Beijing), a leading artificial intelligence medical technology company, on its IPO on the Hong Kong Stock Exchange on an ongoing basis
• Goldman Sachs and China International Capital Corporation (CICC) as joint sponsors for the IPO of Insight Lifetech, a leading medical devices company, on an ongoing basis
• Cryofocus Medtech (Shanghai), a leading medical technology company, on its IPO on the Hong Kong Stock Exchange on an ongoing basis